Download PDF
Pharmacopsychiatry 2012; 45(07): 269-274
DOI: 10.1055/s-0032-1306310
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Neurocognitive Function and Schizophrenia-Proneness in Individuals Dependent on Ketamine, on High Potency Cannabis (‘Skunk’) or on Cocaine

C.J. A. Morgan
1   Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, U.K.
,
S. Duffin
1   Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, U.K.
,
S. Hunt
1   Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, U.K.
,
L. Monaghan
1   Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, U.K.
,
O. Mason
1   Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, U.K.
,
H. V. Curran
1   Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, U.K.
› Author Affiliations
Further Information

Publication History

received 01 July 2011
revised 06 February 2012

accepted 13 February 2012

Publication Date:
17 April 2012 (online)

Also available at
    Permissions and Reprints

Abstract

Background:

Ketamine, psychostimulants and cannabis have all been associated with psychotic phenomena but no study has directly compared users of these drugs.

Aims:

The aim of this study was to assess schizophrenia proneness and neurocognitive function in individuals dependent upon ketamine, cannabis and cocaine.

Method:

130 volunteers – 29 ‘skunk’ users, 22 cocaine users, 21 ketamine users, along with 28 ‘recreational’ poly-drug users and 30 drug-naïve controls – were assessed on the Schizophrenia Proneness Instrument, Adult version (SPI-A). They were specifically asked to rate symptoms when not under the acute influence of a psychoactive drug.

Results:

Ketamine and skunk users manifested the greatest attentional and cognitive disturbances. The symptom profile of the dependent ketamine users was very similar to that of prodromal individuals who transitioned to psychosis.

Conclusions:

Given the recent rapid rise in use of high potency cannabis and of ketamine, these findings are important and clinicians should be careful to rule out the effects of persistent drug use, especially in users of ketamine or skunk, when assessing an individual’s risk of psychosis. A longitudinal study is needed to differentiate which basic symptoms persist following abstention from ketamine and skunk.

Key words

ketamine - cannabis - cocaine - dependence - prodrome - schizophrenia
 

  • References

  • 1 Cannon TD, Cadenhead K, Cornblatt B et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65: 28-37
    CrossrefPubMedGoogle Scholar
  • 2 Miettunen J, Tormanen S, Murray GK et al. Association of cannabis use with prodromal symptoms of psychosis in adolescence. Br J Psychiatry 2008; 192: 470-471
    CrossrefPubMedGoogle Scholar
  • 3 Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res 2007; 151: 151-154
    CrossrefPubMedGoogle Scholar
  • 4 Rosen JL, Miller TJ, D’Andrea JT et al. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res 2006; 85: 124-131
    CrossrefPubMedGoogle Scholar
  • 5 Wylie AS, Scott RT, Burnett SJ. Psychosis due to “skunk”. BMJ 1995; 311: 125
    PubMedGoogle Scholar
  • 6 D’Souza DC, Perry E, MacDougall L et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558-1572
    Google Scholar
  • 7 Brady KT, Lydiard RB, Malcolm R et al. Cocaine-induced psychosis. J Clin Psychiatry 1991; 52: 509-512
    PubMedGoogle Scholar
  • 8 Bartlett E, Hallin A, Chapman B et al. Selective sensitization to the psychosis-inducing effects of cocaine: a possible marker for addiction relapse vulnerability?. Neuropsychopharmacology 1997; 16: 77-82
    CrossrefPubMedGoogle Scholar
  • 9 Manschreck TC, Laughery JA, Weisstein CC et al. Characteristics of freebase cocaine psychosis. Yale J Biol Med 1988; 61: 115-122
    PubMedGoogle Scholar
  • 10 Allen RM, Young SJ. Phencyclidine induced psychosis. Am J Psychiatry 1978; 135: 1081-1084
    PubMedGoogle Scholar
  • 11 Krystal JH, Karper LP, Seibyl JP et al. Subanesthetic effects of the non-competitive NMDA-antagonist, ketamine, in humans. Arch Gen Psychiatry 1994; 51: 199-214
    CrossrefPubMedGoogle Scholar
  • 12 Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 30: 201-225
    PubMedGoogle Scholar
  • 13 Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl) 2006; 188: 408-424
    CrossrefPubMedGoogle Scholar
  • 14 McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry 2008; 7: 148-156
    PubMedGoogle Scholar
  • 15 Klosterkotter J, Hellmich M, Steinmeyer EM et al. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58: 158-164
    CrossrefPubMedGoogle Scholar
  • 16 Simon AE, Cattapan-Ludewig K, Zmilacher S et al. Cognitive functioning in the schizophrenia prodrome. Schizophr Bull 2007; 33: 761-771
    CrossrefPubMedGoogle Scholar
  • 17 Pukrop R, Klosterkotter J. Neurocognitive indicators of clinical high-risk states for psychosis: a critical review of the evidence. Neurotox Res 2010; 18: 272-286
    CrossrefPubMedGoogle Scholar
  • 18 Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of “Ecstasy” users and their experience with the drug. Br J Addict 1992; 87: 1161-1172
    CrossrefPubMedGoogle Scholar
  • 19 Gossop M, Griffiths P, Powis B et al. Severity of dependence and route of administration of heroin, cocaine and amphetamines. Br J Addict 1992; 87: 1527-1536
    CrossrefPubMedGoogle Scholar
  • 20 Wilson B, Cockburn J, Baddeley A. The Rivermead Behavioural Memory Test. Bury St. Edmunds, UK: Thames Valley Test Company; 1985
    Google Scholar
  • 21 Baddeley A, Emslie H, Nimmo-Smith I. The spot the word test: a robust estimate of verbal intelligence based on lexical decision. Br J Clin Psychol 1993; 32: 55-65
    CrossrefPubMedGoogle Scholar
  • 22 Beck AT. The Beck Depression Inventory (BDI). The Psychological Corporation. Harcourt Brace Jovanovitz Inc; USA: 1978
    Google Scholar
  • 23 Spielberger C. State-Trait Anxiety Inventory (Form Y); Palo Alto, California. Mind Garden 1983;
    PubMedGoogle Scholar
  • 24 Schultze-Lutter F, Addington J, Ruhrmann S et al. Schizophrenia Proneness Instrument, Adult version (SPI-A).; Roma, Giovanni Fioriti Editore s.r.l.., 2007
    PubMed
  • 25 Schultze-Lutter F, Steinmeyer EM, Ruhrmann S et al. The dimensional structure of self-reported ‘prodromal’ disturbances in schizophrenia. Clin Neuropsychiatry 2008; 5: 140-150
    PubMedGoogle Scholar
  • 26 Gross G, Huber G, Klosterkotter J et al. Bonner Skala für die Beurteilung von Basissymptomen (BSABS; Bonn Scale for the Assessment of Basic Symptoms). Berlin Heidelberg: Springer; 1987
    Google Scholar
  • 27 Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev 2007; 17: 347-361
    CrossrefPubMedGoogle Scholar
  • 28 Pope Jr HG, Gruber AJ, Hudson JI et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58: 909-915
    CrossrefPubMedGoogle Scholar
  • 29 Honey RA, Honey GD, O’loughlin C et al. Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: an FMRI study. Neuropsychopharmacology 2004; 29: 1203-1214
    CrossrefPubMedGoogle Scholar
  • 30 Beveridge TJ, Gill KE, Hanlon CA et al. Review. Parallel studies of cocaine-related neural and cognitive impairment in humans and monkeys. Philos Trans R Soc Lond B Biol Sci 2008; 363: 3257-3266
    PubMedGoogle Scholar
  • 31 Schultze-Lutter F, Klosterkotter J, Picker H et al. Predicting first episode psychosis by basic symptom criteria. Clin Neuropsychiatry 2007; 4: 11-22
    PubMedGoogle Scholar
  • 32 Muetzelfeldt L, Kamboj SK, Rees H et al. Journey through the K-hole: Phenomenological aspects of ketamine use. Drug Alcohol Depend 2008; 95: 219-229
    CrossrefPubMedGoogle Scholar
  • 33 Cornblatt B, Lencz T, Obuchowski M. The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr Res 2002; 54: 177-186
    CrossrefPubMedGoogle Scholar
  • 34 Moore TH, Zammit S, Lingford-Hughes A et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-328
    Google Scholar
  • 35 Zammit S, Allebeck P, Andreasson S et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002; 325: 1199
    CrossrefPubMedGoogle Scholar
  • 36 Hardwick S, King LA. Home Office Cannabis Potency Study; St Albans. Home Office Scientific Development Branch 2008;
    PubMedGoogle Scholar
  • 37 Morgan CJ, Rees H, Curran HV. Attentional bias to incentive stimuli in frequent ketamine users. Psychol Med 2008; 1-10
    PubMedGoogle Scholar
  • 38 D’Souza DC. Cannabinoids and psychosis. Int Rev Neurobiol 2007; 78: 289-326
    PubMedGoogle Scholar
  • 39 McCambridge J, Winstock A, Hunt N. 5-Year trends in use of hallucinogens and other adjunct drugs amongst UK dance drug users. Eur Addict Res 2007; 13: 57-64
    CrossrefPubMedGoogle Scholar